The two-day meeting will evaluate the achievements of collaboration during the 2021-2023 period. The program also includes the analysis of new projects and proposals so that this continues to be a strategic relationship for the benefit of the peoples and the scientific community of both countries.
The event will be attended by representatives of the Sino-Cuban joint ventures, as well as representatives of different scientific centers with whom they currently have joint plans.
Prior to the event, the Chinese delegation visited the Biotechnology Genetic Engineering Center (CIGB) and the Drug Research and Development Center (CIDEM), which allowed them to learn about innovative projects for the treatment of Alzheimer’s and Parkinson’s, as well as others related to antimicrobial peptides.
Cooperation between Cuba and China in biotechnology has allowed the Hebernem bioproduct, a product developed by CIGB, to be registered in China as a biofertilizer, with work currently being done to achieve its registration as a bionematicide, plus other results.
Chinese and Cuban specialists are also working on products and programs directed against cancer and neurodegenerative diseases.
The president of the Biotechnological and Pharmaceutical Industries Group, BioCubaFarma, Eduardo Martínez, commented on his X account, former twitter, that greater results will be obtained from the integration achieved and the political will of both countries.
He specified that the joint work contributed to the health of Chinese, Cuban and other nationals; joint ventures and research and development laboratories were set up; scientific projects were developed with technology transfer, and joint trademarks were registered, in addition to have launched high-impact publications.
jrr/llp/oda/crc
